LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

Search

Novocure Ltd

Open

SectorGezondheidszorg

17.52 -1.46

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

17.43

Max

18.27

Belangrijke statistieken

By Trading Economics

Inkomsten

-47M

-71M

Verkoop

-295K

174M

EPS

-0.62

Winstmarge

-40.871

Werknemers

1,605

EBITDA

-29M

-63M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+46.23% upside

Dividenden

By Acuity

Volgende Winsten

23 jul 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

506M

2B

Vorige openingsprijs

18.98

Vorige sluitingsprijs

17.52

Nieuwssentiment

By Acuity

50%

50%

146 / 342 Rangschikking in Healthcare

Novocure Ltd Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Over Novocure Ltd

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
help-icon Live chat